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Background: In past, a number of peptides have been reported to possess highly diverse properties ranging from cell
penetrating, tumor homing, anticancer, anti-hypertensive, antiviral to antimicrobials. Owing to their excellent specificity,
low-toxicity, rich chemical diversity and availability from natural sources, FDA has successfully approved a number of
peptide-based drugs and several are in various stages of drug development. Though peptides are proven good drug
candidates, their usage is still hindered mainly because of their high susceptibility towards proteases degradation. We
have developed an in silico method to predict the half-life of peptides in intestine-like environment and to design better
peptides having optimized physicochemical properties and half-life.
Results: In this study, we have used 10mer (HL10) and 16mer (HL16) peptides dataset to develop prediction models
for peptide half-life in intestine-like environment. First, SVM based models were developed on HL10 dataset which
achieved maximum correlation R/R2 of 0.57/0.32, 0.68/0.46, and 0.69/0.47 using amino acid, dipeptide and tripeptide
composition, respectively. Secondly, models developed on HL16 dataset showed maximum R/R2 of 0.91/0.82, 0.90/0.39,
and 0.90/0.31 using amino acid, dipeptide and tripeptide composition, respectively. Furthermore, models that were
developed on selected features, achieved a correlation (R) of 0.70 and 0.98 on HL10 and HL16 dataset, respectively.
Preliminary analysis suggests the role of charged residue and amino acid size in peptide half-life/stability. Based on above
models, we have developed a web server named HLP (Half Life Prediction), for predicting and designing peptides with
desired half-life. The web server provides three facilities; i) half-life prediction, ii) physicochemical properties calculation
and iii) designing mutant peptides.
Conclusion: In summary, this study describes a web server ‘HLP’ that has been developed for assisting scientific
community for predicting intestinal half-life of peptides and to design mutant peptides with better half-life and
physicochemical properties. HLP models were trained using a dataset of peptides whose half-lives have been
determined experimentally in crude intestinal proteases preparation. Thus, HLP server will help in designing peptides
possessing the potential to be administered via oral route (http://www.imtech.res.in/raghava/hlp/).Background
Due to rapid advancement in peptide and peptidomi-
metic techniques, pharmaceutical companies are focusing
towards peptides-based therapeutics [1]. A large number
of peptides like insulin [2], cyclosporine [3], corticotropin
[4] are used for treating various diseases like diabetes and
immunoregulatory disorders [5-7]. Owing to their im-
mense therapeutic importance, peptides have been cu-
rated from literature and stored in form of databases such
as Hemolytik [8], PhytAMP [9], APD2 [10], DAMPD [11],* Correspondence: raghava@imtech.res.in
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unless otherwise stated.CAMP [12], YADAMP [13], CPPsite [14], TumorHoPe
[15], Quorumpeps [16], Brainpeps [17], MilkAMP [18],
DADP [19], LAMP [20] and AVPdb [21] to name a few.
Also, a number of computation tools such as CellPPD [22],
TumorHPD [23], AntiCP [24], AVPpred [25] and Tox-
inPred [26] have been developed to predict and design cell
penetrating, tumor homing, anticancer, antiviral and toxic
peptides, respectively. Presently, most of the therapeutic
peptides are used in the form of injection via subcutane-
ous, intravenous/intramuscular route. In addition, alternate
routes such as pulmonary [27], oral [28,29], intranasal [30],
buccal [31], transdermal [32], ocular [33] and rectal [34]
have been tested. Among all routes of drug delivery, oral is
the most preferred route because oral formulations are lessl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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priate use/reuse of needles. Additionally, orally available
peptides are highly accepted by patients, which increases
the therapeutic value of the drug. However, designing
and formulating an oral peptide has been considered
as a challenging job. This is because of their undesir-
able physicochemical properties like large molecular
size, high susceptibility to enzymatic degradation (pro-
teases), hepatic and renal clearance, etc.
Amongst the above factors, peptide stability is one of the
most difficult tasks to maintain. Their high susceptibility to
proteases in the gut and serum (especially for cationic pep-
tides) and fast degradation rate due to their arginine and
lysine content makes them low orally bioavailable [5,35,36].
A major concern associated with the use of peptide thera-
peutics is improving their stability by protection against
degrading proteases [37]. Although, a number of experi-
mental techniques like peptide modification are available
in order to improve peptide stability with high accuracy
[5,38], yet these experimental procedures are costly and
time consuming. In view of its importance, there is a need
to develop an in silico method for predicting 1) half-life of
peptides as well as 2) prediction of mutations required in
a peptide, in order to increase its intestinal half-life. In
past, computational methods for predicting half-life of
proteins/peptides in blood and kidney cells/cell lines have
been developed. For example, ProtParam is a tool that
helps to estimate half-life of a protein stored in Swiss-
Prot/TrEMBL or a user entered protein. The estimation
of half-life is done for three experimental models namely:
yeast in vivo, mammalian reticulocytes (immature red
blood cells) in vitro and Escherichia coli in vivo [39]. Sta-
bility Prediction tool predicts the stability of HIV-derived
peptides in cytosolic extracts from human peripheral
blood mononuclear cells [40]. SProtP is a web server to
recognize the short-lived proteins (half-life < 30 minutes)
in 293 T cells (a variant of human embryonic kidney cell
line) [41,42]. The N-end rule [43,44] based ‘ProtLifePred
server’ [http://protein-n-end-rule.leadhoster.com/] takes
into account the ubiquitination (a process that involves
post-translational modification of proteins) process of
proteins [45-47] and predicts their stability in S. cerevisiae,
E. coli and mammalian cells. Best of author’s knowledge
there is no computational method developed for design-
ing/predicting stability/half-life of peptides in intestine-
like environment.
In order to facilitate researchers working in the field of
therapeutic peptides, we have developed in silico models
for predicting half-life of peptides. These models were
developed using a set of peptides whose half-lives have
been experimentally determined in crude intestinal pro-
teases preparation [37]. Server developed in this study
can be used to identify minimum mutations in a peptide
required to optimize their half-life.Results
Analysis of half-life data
We computed and analyzed physicochemical properties
of peptides in both HL10 and HL16 datasets to under-
stand relation between property of amino acids and their
half-life. Based on the half-life value, peptides were clas-
sified into two categories peptides having long half-life
(highly stable) and peptides having short half-life (poorly
stable or unstable). Each category have top 20 peptides,
it means 20 peptides having longest half-life were classi-
fied as stable and 20 peptides having shortest half-life
were classified as unstable. We observed that negatively
charged, neutral and tiny types of residues are more
prominent in highly stable peptides (Figure 1A and B).
We have also computed amino acid composition of pep-
tides in highly and lowest/poorly stable peptide datasets.
As shown in Figure 1 (C and D), residues Ala, Asp, Glu,
Gly, Gln, Ser and Thr are abundant in peptide dataset
with longer half-life. As evident from Additional file 1:
Table S3, residues D (Asp), F (Phe), G (Gly), L (Leu), Q
(Gln), R (Arg) and Y (Tyr) show significant differences
(p < 0.05) in amino acid composition in 10mer dataset.
Similarly, residues D (Asp), F (Phe), G (Gly), K (Lys), M
(Met), N (Asn), R (Arg) and Y (Tyr) shows statistically
significant differences (p < 0.05) in amino acid compos-
ition for 16mer dataset (Additional file 1: Table S4).
Prediction of Half-Life
SVM based models on HL10 dataset
The model was developed on HL10 dataset using amino
acid composition-based and achieved maximum R/R2 of
0.57/0.32 with mean absolute error (MAE) 1.87. Simi-
larly models were developed using dipeptide and tripep-
tide composition resulted in R/R2 of 0.68/0.46 and 0.69/
0.47 with MAE 1.44 and 1.38 respectively (Table 1). As
shown in Table 1, performance of binary pattern based
model is poor as compared to composition-based model
with R/R2 of 0.22/0.02 and MAE 1.87. In order to under-
stand role of residues at terminus, models were also de-
veloped using 5-residues from N and C terminal called
5 N-terminal and 5 C-terminal residues. We achieved
maximum R/R2 of 0.39/0.12 and 0.32/0.09 using amino
acid composition of 5 N-terminal and 5 C-terminal resi-
dues, respectively (Table 1). It is evident from the above
results that composition-based models perform better
than models based on binary profile/pattern.
Models developed on selected features
After removing useless features, we developed models for
predicting half-life using following techniques SMOreg,
IBk, KStar and DecisionTable (implemented in Weka
package). We developed composition-based models using
best-selected features/compositions (four type of residues)
and got maximum R/R2 of 0.61/0.35 with MAE 1.42
Figure 1 Physicochemical properties and amino acid composition of top 20 peptides having longest half-life (stable peptides) and top
20 peptides having shortest half-life (unstable peptides). (A) physicochemical properties of 16mer peptides having short and long half-life;
(B) physicochemical properties of 10mer peptides having short and long half-life; (C) average amino acid composition 16mer peptides having
short and long half-life; (D) shows average amino acid composition of 10mer peptides having short and long half-life.
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oped models using best-selected dipeptides (eight type of
dipeptides) and achieved maximum R/R2 of 0.70/0.46
along with MAE 1.22. We also developed model using se-
lected 38 tripeptides and obtained maximum R/R2 of 0.73/
0.35 with MAE 1.39 (Table 2, Additional file 1: Table S1).
SVM based models on HL16 dataset
Similarly, SVM based models were developed on HL16
dataset. The amino acid composition-based model showed
best performance with R/R2 of 0.91/0.82 with MAE 0.18
(Table 3). As shown in Table 3, the dipeptide and tripeptideTable 1 The performance of SVM based models developed on
sequences
Input feature Residues in peptides
Amino acid composition All residues
5 N-terminal
5 C-terminal
Binary pattern All residues
5 N-terminal
5 C-terminal
Dipeptide composition All residues
Tripeptide composition All residuescomposition based models showed an R/R2 of 0.90/0.39,
and 0.90/0.31 with MAE 0.23 and 0.24, respectively. As
compared to composition-based model, the binary pattern
based model again showed poor performance with R/R2 of
0.13/0.01. Next, models were developed using 5 and 10
residues from N and C terminals, respectively. An increase
in model performance with correlation value from 0.57 to
0.77 has been observed for N-terminal 5 to 10 residues
based model developed using amino acid composition
(Table 3). Similarly, the C-terminal based composition
based model shows an increase in model performance with
correlation (R) value of 0.37 to 0.81 and R2 of 0.13 to 0.65.HL10 dataset using different features of peptide
Total attributes R R2 MAE
20 0.57 0.32 1.87
0.39 0.12 2.12
0.32 0.09 1.99
200 0.22 0.02 1.87
100 0.06 −0.06 1.27
100 0.34 0.12 2.01
400 0.68 0.46 1.44
8000 0.69 0.47 1.38
Table 2 The performance of Weka models developed using selected features on HL10 dataset
Total
attributes
Techniques Selected attributes Method R R2 MAE
20 KStar D, G, P, R Amino acid
composition
0.61 0.35 1.42
400 IBk EK, EL, GD, GF, IE, KP, PG, YL Dipeptide
composition
0.70 0.46 1.22
8000 IBk AAH, AGR, AMP, ARE, ASV, DSI, EEK, ELY, ESK, FCI, FGD, FSL, FSS, FYC, GDS, GFG, GLF,
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composition-based model; developed using N and C ter-
minal residues (Table 3).
Models developed on selected features
We identified/selected best features (residues or dipep-
tides or tripeptides) having high correlation with half-life
of peptides. The first model developed using four im-
portant features from the amino acid composition and
achieved maximum R/R2 of 0.97/0.93 along with MAE
0.07 (Table 4, Additional file 1: Table S2). As shown in
Table 4, the three selected dipeptide (CG, GD, GF) re-
sults in R/R2 value of 0.98/0.96 with MAE 0.06. Further
model was developed on selected five attributes from tri-
peptide composition shows equal performance with cor-
relation coefficient value of 0.98 (Table 4, Additional file
1: Table S2).
Development of web server/software
Based on above study, we developed a web server for
predicting intestinal half-life of peptides to design stable
peptides through mutant generation and whole protein
scanning. HLP server has three main modules called
Peptide, Protein and Batch module. First module i.e.,
Peptide, allows users to submit single peptide at a time
to the web server for predicting its intestinal half-lifeTable 3 The performance SVM based models developed on H
Input features Residues in peptides T










Dipeptide composition All residues
Tripeptide composition All residuesand designing mutants which may have better half-life
and physicochemical properties than original peptide.
Protein module allows a user to submit a protein for
scanning to find peptide having high intestinal half-life.
Furthermore, it allow to generate mutant peptides corre-
sponding to user-selected peptide. Third module i.e.,
Batch, designed for high throughput scanning where a
user can submit a large number of peptides for filtering
best peptides (having high intestinal half-life and desired
physicochemical properties). Our HLP server implement
total six type of models; these can be divided in two
classes: SVM based models (implemented using SVMlight
package) and Weka based models (implemented using
WEKA package). Our SVM based models implemented
using following type of information of peptides; i) dipep-
tide composition in case of 10mer peptides, ii) amino
acid composition for 16mer peptides and iii) type of
composition depend on peptide length in case of user-
selected sequence length. In case of Weka based models,
following techniques and peptide information is used; i)
IBK model using eight dipeptides (EK, EL, GD, GF, IE,
KP, PG, YL) for 10mer peptides, ii) DecisionTable using
three dipeptides (CG, GD, GF) for 16mer peptides and
iii) model selection depends on peptide length in case of
user-selected sequence length. The HLP web server was
developed using Perl, CGI and HTML languages; it isL16 dataset using composition and binary pattern
otal attributes R R2 MAE





320 0.13 0.01 0.18
100 0.17 0.02 0.20
100 0.03 −0.002 0.18
200 0.22 0.02 0.18
200 0.09 −0.002 0.18
400 0.90 0.39 0.23
8000 0.90 0.31 0.24
Table 4 The performance of various models (Weka) using selected features on HL16 dataset
Total attributes Techniques Selected attributes Method R R2 MAE
20 DecisionTable C, D, G, R Amino acid composition 0.97 0.93 0.07
400 DecisionTable CG, GD, GF Dipeptide composition 0.98 0.96 0.06
8000 DecisionTable AQC, EAQ, FGD, GFG, QCG Tripeptide composition 0.98 0.96 0.06
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imtech.res.in/raghava/hlp/.
Discussion
Although a number of peptides have entered in market
against various indications (such as diabetes, hypertension,
cancer, HIV, etc.) still one of the major challenges in suc-
cess of peptide-based therapy is their low half-life in serum
and gut. There are number of factors responsible for de-
grading or shortening half-life of peptides [5]; where in
silico designing of peptides seems to be a promising field in
the area of peptide based therapy. The presence of intes-
tinal proteases is one of the major factors behind degrad-
ation of peptides. In vitro peptide stability screening is
considered to be the most difficult and time-consuming
task. In order to assist scientific community to screen
stable peptide in intestine-like environment, we have made
a systematic attempt in this direction. In this study, models
have been developed for predicting half-life of peptides on
dataset derived from Gorris et al., 2009, where half-lives of
peptides have been experimentally determined in the pres-
ence of crude intestinal proteases (high concentration).
Firstly, they calculated half-life of peptides in undiluted
proteolytic solution and then it has been subsequently ex-
trapolated from results obtained from diluted solutions.
The analysis based on these datasets suggest that charge
and size of an amino acid are the two major factors gov-
erning the peptide stability. As reported in previous studies
on bioactive peptides [22-24], positively charge amino acids
Arg and Lys are preferred among majority of these kind of
peptides while the present study reports these residues re-
sponsible to decrease peptide’s intestinal half-life. There-
fore, the residues affecting peptide’s half-life and bioactivity
should be optimized simultaneously while designing highly
stable and potent bioactive peptides. The presence of large
size amino acids such as Phe, Arg, Tyr and Trp will in-
crease protease susceptibility and tiny amino acids (such as
Gly, Ala, Ser, Thr) may help in their stabilization. Among
these large-size amino acids, three (Phe, Tyr, Trp) belong
to aromatic class and are also responsible for the decreased
half-life. HLP models, developed on a small dataset shows
good correlation (R) of 0.70 and 0.98 between predicted
and actual half-life value on HL10 and HL16 dataset, re-
spectively. One of two major limitations of our method is
that it is not suitable for predicting the stability of modified
peptides like N-terminal/C-terminal modification or effect
of disulphide bond in a peptide. Therefore, our model isonly suitable for predicting the stability of peptide com-
posed of natural amino acids without any chemical modifi-
cations. Another limitation of the present study is the
presence of small dataset in training and testing the half-
life models due to unavailability of large dataset on peptide
half-life in intestine from literature. The actual half-lives
have been calculated in highly concentrated environment.
Gorris et al. assume that the half-life values would be very
high in real life. Unfortunately, they haven’t mentioned
quantitatively, how high these half-lives values would be in
real life. Thus, the half-life dataset helps in estimating half-
lives of peptides relatively rather than in absolute terms.
Just for our satisfaction and to test how good the models
will work on peptides having very high half-lives, we devel-
oped new models after multiplying peptide’s actual half-life
with 10 and 1000. As evident from Additional file 2: Tables
S1-S6, half-life prediction models performs equally well for
higher half-life containing peptides, irrespective of very
high/low half-life. Hence, HLP can prove to be a extremely
good resource to relatively estimate the half-life of peptides
in intestine like environment. Additionally, this can help in
improving half-life of peptide(s) half-life by mutating resi-
due. We hope that our study will be useful to scientific
community for designing/prediction of stable peptides and
thus helpful in solving the major barrier in peptide based
drug development.Conclusion
There is a growing demand of peptide-based drugs but the
major bottleneck in their development is their short half-
life. The present study can provide an efficient method to
design therapeutic peptides having better half-life and
physicochemical properties. We hope that our method
would promote the usage of various types of therapeutic
peptides in drug discovery and development.Methods
Datasets
In this study, we have used two datasets called HL10 and
HL16 for developing prediction models. The datasets con-
taining peptides with their half-life, were obtained from
Gorris et al., 2009 [37]. HL10 dataset consists of 189 pep-
tides with their half-life value varies from 0.0008 -
40.1296 seconds. HL16 dataset consists of 186 peptides
with their half-life value varies from 0.0008 - 6.4211
seconds. Additionally, the distribution of half-lives (for
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five by Gorris et al., 2009.
Input features
Physicochemical properties
It is well established that activity or function of a peptide
or protein depends on its amino acid sequence. Each
amino acid has unique set of physicochemical properties
like hydrophobicity, polarity, charge, size. Thus each pep-
tide has different physicochemical properties depending on
type of residue it contains. Thus, physicochemical proper-
ties of peptide play a significant role in determining the ac-
tivity of peptides; therefore we had calculated more than
15 different properties of peptides like hydrophobicity, vol-
ume, isoelectric point, flexibility [48-51].
Residue composition as input features
In the past, it has been observed that amino acids compos-
ition encapsulates the protein information. Based on this
approach, numbers of methods have been developed like
protein folding rate prediction, sub-cellular localization
prediction [51,52]. In this study, we computed amino acid,
dipeptide and tripeptide composition and used as input fea-
ture for developing prediction models. These compositions
are represented by a vector of dimension 20, 400, and 8000
for residue/amino acid, dipeptide and tripeptide compos-
ition respectively [53].
Binary pattern
Each amino acid of a peptide is represented by binary
pattern of 20, where 1′s represents the presence of con-
cerned amino acid at that position and 0′s for the ab-
sence of other 19 amino acids (e.g. Ala is represented by
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0) [22]. Thus, a vector
of dimension N X 20 is used to represent the peptide of
length N (size of peptide).
Models based on machine learning techniques
In this study various machine-learning techniques have
been used for developing regression models. In order to
implement support vector machine for developing models
we used commonly used highly efficient software called
SVMlight. This package allows to implement various kernels
(e.g., linear, polynomial, RBF) as well as it allow to tune
various parameters.
In addition to SVMlight, we also used Weka, a Java based
software package having various machine learning and fea-
ture selection algorithms [54]. In this study, we have used
SMOreg (Sequential Minimization Optimization) module
of Weka for building model for predicting half-life/stability
of peptides. We also used IBK, KStar and DecisionTable
based classifier, implemented in Weka for model building
and optimization.Feature selection
Previously, studies have shown that all input features are
not equally important during the construction of an in
silico model [55]. Thus, feature selection seems to be more
relevant in order to find out the most important and con-
tributing input features. In this study for feature selection,
we have used CfsSubsetEval attribute evaluator with Best-
First (with parameters: −D 1 -N 5) search method (using
full training set as attribute selection mode) implemented
in Weka software for both HL10 and HL16 dataset.Evaluation of performance
The performance of the models was evaluated by
employing a five-fold cross-validation technique. The
whole dataset is divided into five sets in such a way that
every time four sets are used for training and one set for
testing. This process is repeated five times in such a way
that each set is used for testing. Once the model is con-














































Where yi and xi represent predicted and actual half-
life values for ith peptide. N is total number of peptides.
SD is the sum of the squared deviations between the ac-
tivities of the test set and mean activities of the training
peptides. The value of correlation coefficient (R) and co-
efficient of determination (R2) is used to measure the
quality of model. The value of R varies from −1 to +1
while R2 is from 0 to 1. The negative value of R shows
the negative correlation with a particular property or
feature. Thus, higher the value of R and R2, better will
be the quality of model in term of prediction of half-life
of peptides.Availability and requirements
We have developed a web server HLP, freely available
for predicting half-life of peptides in intestine-like envir-
onment. This web server was developed using PERL,
CGI and HTML programming languages.
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Additional file 1: Weka based results for both HL10 (Table S1) and
HL16 (Table S2) using selected features. Differences in amino acid
composition for longest half-life (stable) Vs shortest half-life (unstable)
containing 10mer (Table S3) and 16mer peptides (Table S4).
Additional file 2: Performance of SVM and Weka based models
(Tables S1-S6) after multiplying their actual half-life with 10 and
1000. Longest half-life (Stable) and shortest half-life containing 10mer
(Table S7) and 16mer peptides (Table S8).
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